human leukocyte antigen News
-
CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service
CD Genomics is a leading global life sciences company committed to providing the research community with high-quality long-read sequencing services, from Oxford Nanopore to PacBio SMRT sequencing. The Product Manager of the Long-Read Sequencing Division announced the launch of the Human Leukocyte Antigen (HLA) Typing service to support high-resolution HLA typing in a rapid and cost-efficient ...
By CD Genomics
-
CD Genomics Launches Mature HLA Typing Solutions Enabling Precision Immune Profiling
CD Genomics, a renowned leader in genomics and next-generation sequencing (NGS) applications, has unveiled its cutting-edge HLA typing solutions, revolutionizing immune profiling and transplantation compatibility assessment. The human leukocyte antigen (HLA) system plays a crucial role in immune regulation and determining transplantation compatibility. HLA typing, the process of identifying ...
By CD Genomics
-
CD Genomics Launched HLA Genotyping Service to Help Scientists Better Understand the Mechanisms of MHC
CD Genomics is one of the leading service providers in the area of genomic sequencing and data analysis as well as other genomic-related technologies to fully supports customers’ research projects. HLA genotyping service is one such. CD Genomics provides accurate and reliable HLA genotyping service based on next-generation sequencing (NGS) technology that generates unambiguous, ...
By CD Genomics
-
Obsidian Therapeutics to Present Preclinical Data from cytoTIL15™ Program at the American Associate of Cancer Research (AACR) Annual Meeting 2022
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present preclinical data highlighting its cytoTIL15™ program during a poster session at the upcoming AACR Annual Meeting 2022. The abstract title has been posted to the AACR Online Itinerary Planner, will be published in the online Proceedings of the AACR, and is ...
-
BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type. Bria-Pros™ is a novel off-the-shelf personalized immunotherapy approach to treating prostate cancer. Waisman Biomanufacturing has entered an agreement with BriaCell to ...
-
T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies
T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, today announced the successful completion of a $110 million Series B financing. The financing was led by Fidelity Management & Research Company, LLC., with participation from other new investors including, LSP, Qatar Investment Authority (QIA), ...
By T-Knife GmbH
-
SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors
WATERTOWN, Mass.--(BUSINESS WIRE)-- SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the company’s lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors. Fast ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you